BMRN

54.68

2.44% -1.37

Handel nachbörslich: 55.00 0.32 +0.59%

Biomarin Pharmaceutical Inc (BMRN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$56.05

Offen:

$56.32

24-Stunden-Volumen:

2.62M

Relative Volume:

1.01

Marktkapitalisierung:

$10.58B

Einnahmen:

$3.29B

Nettoeinkommen (Verlust:

$268.74M

KGV:

39.90

EPS:

1.3704

Netto-Cashflow:

$759.12M

1W Leistung:

-0.21%

1M Leistung:

-15.53%

6M Leistung:

+1.07%

1J Leistung:

+3.27%

1-Tages-Spanne:

$54.44

$56.53

1-Wochen-Bereich:

$53.93

$57.59

52-Wochen-Spanne:

$49.26

$70.98

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Firmenname

Biomarin Pharmaceutical Inc

Sektor

Healthcare (1052)

Branche

Biotechnology (594)

Telefon

(415) 506-6700

Adresse

105 DIGITAL DRIVE, NOVATO, CA

Mitarbeiter

3,221

Twitter

Nächster Verdiensttermin

2026-10-26

Neueste SEC-Einreichungen

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, MRNA, REGN, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BMRN Biomarin Pharmaceutical Inc	54.68	10.58B	3.29B	268.74M	759.12M	1.3704
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-10-15	Fortgesetzt	UBS	Buy
2026-10-12	Hochstufung	Raymond James	Outperform → Strong Buy
2026-08-19	Eingeleitet	BMO Capital Markets	Outperform
2026-05-19	Eingeleitet	Citigroup	Buy
2026-05-11	Fortgesetzt	Goldman	Neutral
2026-04-27	Fortgesetzt	Morgan Stanley	Overweight
2026-01-28	Fortgesetzt	Barclays	Overweight
2026-01-20	Hochstufung	Canaccord Genuity	Hold → Buy
2025-12-03	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-11-06	Herabstufung	Stifel	Buy → Hold
2025-09-08	Eingeleitet	H.C. Wainwright	Neutral
2025-09-03	Eingeleitet	Raymond James	Outperform
2025-07-03	Fortgesetzt	Morgan Stanley	Overweight
2025-02-24	Hochstufung	Oppenheimer	Perform → Outperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-10-30	Herabstufung	William Blair	Outperform → Mkt Perform
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-08-20	Hochstufung	Bernstein	Mkt Perform → Outperform
2024-05-17	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-05-14	Eingeleitet	Evercore ISI	Outperform
2023-11-15	Eingeleitet	Wells Fargo	Overweight
2023-10-23	Hochstufung	Bernstein	Underperform → Mkt Perform
2023-09-28	Eingeleitet	Raymond James	Mkt Perform
2023-09-18	Eingeleitet	UBS	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Perform
2023-07-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-06-14	Fortgesetzt	Credit Suisse	Outperform
2023-03-21	Eingeleitet	Bernstein	Underperform
2023-02-22	Herabstufung	Oppenheimer	Outperform → Perform
2023-02-21	Eingeleitet	Citigroup	Neutral
2023-01-30	Eingeleitet	BMO Capital Markets	Market Perform
2023-01-18	Eingeleitet	Canaccord Genuity	Hold
2022-10-31	Hochstufung	Oppenheimer	Perform → Outperform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Overweight
2022-06-13	Fortgesetzt	Wedbush	Neutral
2022-04-25	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	Hochstufung	William Blair	Mkt Perform → Outperform
2021-10-07	Fortgesetzt	Jefferies	Buy
2021-09-09	Hochstufung	Stifel	Hold → Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-04	Fortgesetzt	Guggenheim	Buy
2021-03-01	Hochstufung	Evercore ISI	In-line → Outperform
2020-08-20	Herabstufung	Citigroup	Buy → Neutral
2020-08-20	Herabstufung	William Blair	Outperform → Mkt Perform
2020-08-19	Herabstufung	Evercore ISI	Outperform → In-line
2020-08-19	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	Herabstufung	Stifel	Buy → Hold
2020-07-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	Bestätigt	Citigroup	Buy
2020-01-28	Eingeleitet	BMO Capital Markets	Market Perform
2020-01-27	Eingeleitet	BMO Capital Markets	Market Perform
2020-01-24	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	Hochstufung	Barclays	Equal Weight → Overweight
2019-11-12	Eingeleitet	SunTrust	Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Citigroup	Buy
2019-04-09	Fortgesetzt	Raymond James	Outperform
2019-01-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-07	Bestätigt	Stifel	Buy
2018-08-03	Bestätigt	Stifel	Buy

Alle ansehen

Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten

Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation - Investing.com

Oct 12, 2026

Why is BioMarin Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada

Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation By Investing.com - Investing.com South Africa

Oct 12, 2026

Oct 10, 2026

Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 10, 2026

Oct 09, 2026

RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 09, 2026

BioMarin to present data on achondroplasia treatment at ASBMR - Investing.com

Oct 09, 2026

New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan

Oct 09, 2026

Oct 08, 2026

BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention? - Yahoo Finance

Oct 08, 2026

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 08, 2026